Innovative RNA-based therapeutics for serious disease

Thalia Therapeutics is a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease.

We are focused on unlocking the full therapeutic potential of RNA by overcoming the fundamental challenges of delivery, enabling targeted, scalable and clinically meaningful medicines for patients with significant unmet medical needs.

approach pipeline technology

Advancing RNA medicines through delivery innovation

RNA therapeutics have the potential to transform the treatment of disease, but effective delivery remains the key challenge. Thalia Therapeutics is developing proprietary RNA delivery technologies (Nuvec®) designed to address these challenges, enabling multi-RNA loading, flexible targeting and the potential for oral delivery.

Nuvec® is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. Nuvec® silica nanoparticles can be readily functionalised to target specific tumour types or organs and have a large surface area, allowing high loading and delivery of RNA drug cargos to their site of action.

By combining delivery innovation with a disciplined, capital-efficient development strategy, we are building a diversified pipeline with multiple value drivers across high-growth therapeutic areas.

A diversified and expanding pipeline

Thalia Therapeutics has a growing pipeline of RNA-based programmes across oncology and cardiovascular disease, including:

A dual-target cardiovascular siRNA programme addressing a major unmet need in Atherosclerotic Cardiovascular Disease (ASCVD)
A proprietary RNA delivery technology with broad applicability across multiple RNA modalities and indications

Our strategy is to advance internal programmes to generate high-quality clinical and preclinical data while creating opportunities for partnering and licensing.

Proprietary RNA delivery capabilities.

Thalia Therapeutics has developed proprietary RNA delivery technologies (Nuvec®) designed to overcome key barriers to RNA therapeutic development. These technologies enable:

Multi-RNA loading
Flexible targeting
Broad applicability across RNA modalities
Potential for oral delivery

In addition to delivering RNA, the Nuvec® delivery system can be functionalised by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. Nuvec® particles carrying RNA and functionalised with a tumour targeting peptide have been shown to be effectively taken up specifically into lung cancer cells, where they release their RNA cargo.

Our delivery technologies are scalable and designed for repeatable application across multiple therapeutic areas, creating opportunities both within Thalia Therapeutics’ own pipeline and through external partnerships.

Innovative RNA-based therapeutics for serious disease

Advancing RNA medicines through delivery innovation

A diversified and expanding pipeline

Proprietary RNA delivery capabilities.

News from Thalia

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.